Merck (known as MSD outside the US and Canada) and Mayo Clinic have entered a multi-year collaboration to harness artificial intelligence for accelerating drug discovery and development. The partnership combines Merck’s expertise in oncology, immunology, and neuroscience with Mayo Clinic’s vast clinical data and research capabilities to build AI models that identify novel targets, optimize candidates, and improve clinical trial design.
Glimpse:
The collaboration focuses on co-developing AI and machine learning models trained on de-identified patient data from Mayo Clinic and Merck’s R&D insights. Initial efforts target oncology and immunology programs, with potential expansion to other therapeutic areas. By integrating multimodal data (genomics, imaging, EHRs, and real-world evidence), the partnership aims to shorten discovery timelines, increase success rates, and bring more effective therapies to patients faster.
Merck and Mayo Clinic have announced a strategic R&D collaboration centered on artificial intelligence to transform the drug discovery and development process. The multi-year agreement, unveiled in early 2026, leverages Mayo Clinic’s unparalleled clinical data repository and Merck’s deep therapeutic area knowledge to create next-generation AI tools that address key bottlenecks in bringing new medicines to market.
Core elements of the partnership include:
AI model co-development building multimodal AI systems that integrate genomic, proteomic, imaging, clinical, and real-world data to uncover novel drug targets and mechanisms Target identification & validation using AI to prioritize biologically relevant targets with higher probability of success in oncology, immunology, and potentially neuroscience Candidate optimization predictive modeling for drug-like properties, toxicity risks, and patient subgroup response Clinical trial enhancement AI-driven patient stratification, site selection, and real-time monitoring to improve trial efficiency and diversity Responsible AI framework joint governance on data privacy, bias mitigation, explainability, and ethical use, aligned with HIPAA, GDPR, and emerging global standards
The collaboration emphasizes federated and privacy-preserving approaches to allow secure data use without compromising patient confidentiality. Mayo Clinic contributes de-identified, high-quality longitudinal patient data, while Merck brings chemistry expertise, high-throughput screening capabilities, and translational research infrastructure.
This alliance reflects a broader industry shift toward AI-enabled, data-rich partnerships that combine academic clinical insight with pharmaceutical development scale. It aims to reduce the high failure rates and long timelines that characterize traditional drug discovery, ultimately delivering more precise, effective therapies to patients.
The partnership will begin with focused oncology and immunology projects, with results expected to inform broader Merck pipeline strategies and potentially influence future AI standards in healthcare R&D.
“By combining Mayo Clinic’s clinical depth with Merck’s discovery expertise and AI innovation, we can uncover new possibilities that were previously out of reach.”
By
HB Team
Related News
